WT1 肾母细胞瘤（鼠单克隆抗体）

广州健仑生物科技有限公司

WT1是位于染色体11p13的抑癌基因，可识别间皮细胞增生、恶性间皮瘤、卵巢囊腺癌、性腺母细胞瘤、肾母细胞瘤及结缔组织增生性小圆细胞肿瘤。可用于研究促结缔组织增生的小圆细胞瘤和Ewing肉瘤及原始神经外胚层肿瘤。

我司还提供其它进口或国产试剂盒：登革热、疟疾、流感、A链球菌、合胞病毒、腮病毒、乙脑、寨卡、黄热病、基孔肯雅热、克锥虫病、违禁品滥用、肺炎球菌、军团菌、化妆品检测、食品安全检测等试剂盒以及日本生研细菌分型诊断血清、德国SiFin诊断血清、丹麦SSI诊断血清等产品。

欢迎咨询

欢迎咨询

WT1 肾母细胞瘤（鼠单克隆抗体）

【产品介绍】

细胞定位：细胞核

克隆号：6F-H2

同型：IgG

适用组织：石蜡/冰冻

阳性对照：间皮瘤

抗原修复：热修复（EDTA）

抗体孵育时间：30-60min

WT1

想了解更多的产品及服务请扫描下方二维码：

【公司名称】 广州健仑生物科技有限公司
【市场部】     欧

【】 
【腾讯  】 
【公司地址】 广州清华科技园创新基地番禺石楼镇创启路63号二期2幢101-103室

在这些信息的基础上，我们可以同步细胞动态，在引入转基因时让大多数细胞处于抗原抗体状态。已经有前期工作表明，重编程动态受到一些限速步骤的调控。比如，去除组蛋白乙酰化的一个抑制子，可以使体外重编程的效率达到几乎100%。此外，引入OSKM也会刺激甲基化等细胞过程，以维持内稳态。对于研究这些过程的动态而言，定量技术将特别有优势。FACS和拉曼光谱才刚开始用于细胞重编程的定量研究，就已经表现出了很大的潜力。
细胞重编程受到公众关注，主要是因为它在疾病模拟和医疗保健中的应用。神经退行性疾病的患者特别能从这一技术中获益，因为生成神经元的iPS方案要优于其他细胞类型，而且患者神经元通常很难获取。目前，细胞重编程技术研究特定基因组突变引起的疾病，因为重编程会重设表观基因组。尽管有证据表明，iPS技术也能用来研究复杂基因组改变引起的疾病，但目前的模型一般不足以研究异常细胞网络或动态引发的疾病。

Based on this information, we can synchronize cellular dynamics, allowing most cells to be in an antigen-antibody state upon introduction of the transgene. Preliminary work has shown that reprogramming is dynamically limited by some rate-limiting steps. For example, removing a suppressor of histone acetylation can make reprogramming nearly 100% efficient in vitro. In addition, the introduction of OSKM also stimulates cellular processes such as methylation to maintain homeostasis. Quantitative techniques will be particularly advantageous for studying the dynamics of these processes. FACS and Raman spectroscopy have just begun to be used in quantitative studies of cell reprogramming and have shown great potential.
Cell reprogramming has received public attention primarily because of its use in disease simulation and healthcare. In particular, patients with neurodegenerative diseases benefit from this technique because the iPS regimen that produces neurons is superior to other cell types and is often difficult to obtain in patient neurons. Currently, cell reprogramming is best suited to study diseases caused by specific genomic mutations because reprogramming resets the epigenome. Although there is evidence that iPS technology can also be used to study diseases caused by complex genome changes, current models are generally not adequate for studying abnormal cell networks or dynamically induced diseases.